INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2014年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页码：E144 / E145
页数：2
相关论文
共 50 条
  • [1] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [2] Overview and Management of Cardiac and Pulmonary Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Wang, Michael
    Cheng, Jie
    ONCOLOGY-NEW YORK, 2013, 27 : 24 - 30
  • [3] Incidence and Management of Renal Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Shah, Jatin J.
    ONCOLOGY-NEW YORK, 2013, 27 : 19 - 23
  • [4] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
  • [5] From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma
    Siegel, David S.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2013, 4 (06) : 354 - 365
  • [6] Cardiac and pulmonary safety profile of patients with relapsed and/or refractory multiple myeloma from four phase 2 studies of single-agent carfilzomib
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    LEUKEMIA & LYMPHOMA, 2013, 54 : 19 - 19
  • [7] Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    BLOOD, 2012, 120 (21)
  • [8] Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
    Moore, Donald C.
    Arnall, Justin R.
    Harvey, R. Donald
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 613 - 622
  • [9] Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2015, 11 (15) : 2121 - 2136
  • [10] Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
    Zhao, Fang
    Yang, Bo
    Wang, Juan
    Zhang, Rui
    Liu, Jing
    Yin, Fenglei
    Xu, Weixing
    He, Chunyuan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 1525 - 1531
12345